Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims/Hypothesis:Gestational exposures such as dietary changes can alter offspring phenotype through epigenetic modifications and promote increased risk for specific diseases, such as metabolic syndrome. We hypothesized that high-fat diet (HFD) during late gestation would lead increased risk for insulin resistance and hyperlipidemia via associated epigenetic alterations in tissue adipocytokine genes.Methods:Offspring mice of mothers fed a HFD during late gestation (HFDO) were weighed and their food intake measured weekly till age 20 weeks at which time glucose and insulin tolerance tests, plasma lipid and adipocytokine levels were assessed, as well as mRNA expression in visceral fat. Adipocytokine gene methylation levels in visceral fat, liver and muscle were also assayed.Results:HFDO mice had increased weight accrual and food intake, and exhibited insulin resistance, hyperlipidemia and hyperleptinemia, as well as hypoadiponectinemia. Furthermore, increased methylation of adiponectin and leptin receptor, and decreased methylation of leptin genes with unchanged glucagon-like peptide-1 methylation patterns emerged in HFDO mice.Conclusions:Taken together, late gestational HFD induces increased risk of metabolic syndrome in the progeny, which is coupled with hypoadiponectinemia as well as with leptin resistance, and concomitant presence of selective tissue-based epigenetic changes among adipocytokine genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Svetkey, L. P. (2008) · JAMA · doi:10.1001/jama.299.10.1139 · Cited by 748
Four-year weight losses in the Look AHEAD study: factors associated with long-term success
Wadden, T. A., Neiberg, R. H., Wing, R. R., Clark, J. M., Delahanty, L. M., Hill, J. O., Krakoff, J., Otto, A., Ryan, D. H., Vitolins, M. Z., et al. (2011) · Obesity · doi:10.1038/oby.2011.230 · Cited by 465
Self-citationComparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Semaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227
Self-citationKornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“, 2013 (31) NCT00781937 56 Liraglutide Placebo 3/212 0/210 45.”
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
Duarte, A. I., Sjögren, M., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Björkqvist, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27121-w · Cited by 25
Metadata
- Authors
- Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., Aronne, L., & on behalf of the NN8022-1923 Investigators
- Venue
- International Journal of Obesity
- Published
- 2014-10-14
- Volume
- 39
- Issue
- 1
- Pages
- 187-187
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4256297099
- Cited by
- 40
- References
- 5
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.